Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference
Annovis Bio (NYSE: ANVS) has announced its participation in Oppenheimer's 35th Annual Healthcare Life Sciences Conference. CEO Maria Maccecchini, Ph.D., will deliver a presentation on February 11, 2025, from 12:40 to 1:10 p.m. ET through the conference's virtual platform.
The presentation will focus on the company's recent developments, particularly highlighting progress in their pivotal Phase 3 trial for early Alzheimer's disease. Dr. Maccecchini will also discuss strategic initiatives regarding a New Drug Application (NDA) for buntanetap, which is being developed as both a symptomatic and potentially disease-modifying treatment.
The conference is a significant industry event that connects leading healthcare and life sciences companies with investors, offering a platform for executives to share insights on industry trends, innovations, and investment opportunities.
Annovis Bio (NYSE: ANVS) ha annunciato la sua partecipazione alla 35ª Conferenza Annuale sulla Sanità e le Scienze della Vita di Oppenheimer. Il CEO Maria Maccecchini, Ph.D., presenterà il 11 febbraio 2025, dalle 12:40 alle 13:10 ET tramite la piattaforma virtuale della conferenza.
La presentazione si concentrerà sugli sviluppi recenti dell'azienda, evidenziando in particolare i progressi nel loro trial di Fase 3 cruciale per l'Alzheimer nella sua fase iniziale. La Dr.ssa Maccecchini discuterà anche delle iniziative strategiche relative a una Domanda di New Drug Application (NDA) per buntanetap, che viene sviluppato sia come trattamento sintomatico che potenzialmente modificante la malattia.
La conferenza è un evento significativo per l'industria che connette le principali aziende nel settore sanitario e delle scienze della vita con gli investitori, offrendo una piattaforma per i dirigenti per condividere intuizioni su tendenze del settore, innovazioni e opportunità di investimento.
Annovis Bio (NYSE: ANVS) ha anunciado su participación en la 35ª Conferencia Anual de Oppenheimer sobre Ciencias de la Salud. La CEO María Maccecchini, Ph.D., hará una presentación el 11 de febrero de 2025, de 12:40 a 1:10 p.m. ET a través de la plataforma virtual de la conferencia.
La presentación se centrará en los desarrollos recientes de la empresa, destacando especialmente el progreso en su ensayo de Fase 3 crucial para la enfermedad de Alzheimer en sus etapas iniciales. La Dra. Maccecchini también discutirá las iniciativas estratégicas relacionadas con una Solicitud de Nuevo Medicamento (NDA) para el buntanetap, que se desarrolla como un tratamiento sintomático y potencialmente modificador de la enfermedad.
La conferencia es un evento significativo de la industria que conecta a las principales empresas de atención médica y ciencias de la vida con inversores, ofreciendo una plataforma para que los ejecutivos compartan perspectivas sobre tendencias, innovaciones y oportunidades de inversión en el sector.
안노비스 바이오 (NYSE: ANVS)가 오펜하이머 제35회 연례 헬스케어 생명과학 컨퍼런스에 참가할 것이라고 발표했습니다. 최고경영자 마리아 마체치니 박사가 2025년 2월 11일 오후 12:40부터 1:10까지 ET 시간에 이 컨퍼런스의 가상 플랫폼을 통해 발표를 진행합니다.
이번 발표는 회사의 최근 발전에 초점을 맞추며, 특히 조기 알츠하이머 병을 위한 중요한 3상 시험에서의 진전을 강조합니다. 마체치니 박사는 또한 buntanetap에 대한 신약 신청(NDA)의 전략적 이니셔티브에 대해 논의할 것입니다. 이 약물은 증상 치료와 함께 질병 수정 가능성을 가진 치료제로 개발되고 있습니다.
이번 컨퍼런스는 업계를 대표하는 헬스케어 및 생명과학 회사들과 투자자들을 연결하는 중요한 산업 행사로, 경영진들이 산업 동향, 혁신 및 투자 기회에 대한 통찰을 공유할 수 있는 플랫폼을 제공합니다.
Annovis Bio (NYSE: ANVS) a annoncé sa participation à la 35ème Conférence Annuelle d'Oppenheimer sur la Santé et les Sciences de la Vie. La PDG Maria Maccecchini, Ph.D., fera une présentation le 11 février 2025, de 12h40 à 13h10 ET via la plateforme virtuelle de la conférence.
La présentation mettra l'accent sur les récentes évolutions de l'entreprise, en soulignant en particulier les avancées de leur essai de Phase 3 décisif pour la maladie d'Alzheimer précoce. Dr. Maccecchini discutera également des initiatives stratégiques concernant une demande de nouvel médicament (NDA) pour le buntanetap, qui est développé à la fois comme un traitement symptomatique et potentiellement modifiant la maladie.
Cette conférence est un événement significatif de l'industrie qui connecte les principales entreprises du secteur de la santé et des sciences de la vie avec les investisseurs, offrant une plateforme pour que les dirigeants partagent des idées sur les tendances du secteur, les innovations et les opportunités d'investissement.
Annovis Bio (NYSE: ANVS) hat seine Teilnahme an der 35. jährlichen Healthcare und Life Sciences-Konferenz von Oppenheimer bekannt gegeben. CEO Maria Maccecchini, Ph.D., wird am 11. Februar 2025 von 12:40 bis 13:10 Uhr ET über die virtuelle Plattform der Konferenz präsentieren.
Die Präsentation wird sich auf die jüngsten Entwicklungen des Unternehmens konzentrieren und insbesondere den Fortschritt in ihrer entscheidenden Phase-3-Studie zur frühen Alzheimer-Krankheit hervorheben. Dr. Maccecchini wird auch strategische Initiativen im Zusammenhang mit einem New Drug Application (NDA) für buntanetap besprechen, das sowohl als symptomatische als auch potenziell krankheits-modifizierende Behandlung entwickelt wird.
Die Konferenz ist eine bedeutende Branchenveranstaltung, die führende Unternehmen im Gesundheitswesen und in den Lebenswissenschaften mit Investoren verbindet und eine Plattform für Führungskräfte bietet, um Einblicke zu Branchentrends, Innovationen und Investitionsmöglichkeiten zu teilen.
- None.
- None.
MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that its CEO, Maria Maccecchini, Ph.D., will present at the Oppenheimer's 35th Annual Healthcare Life Sciences Conference.
Presentation details
- Date: February 11, 2025
- Time: 12:40 – 1:10 p.m. ET
Attendees can access the live presentation through the conference's virtual platform.
Dr. Maccecchini will discuss the Company’s latest advancements, highlighting the progress of the pivotal Phase 3 trial in early AD and strategic initiatives toward a New Drug Application (NDA) for buntanetap as both a symptomatic and potentially disease-modifying treatment.
Oppenheimer's Annual Healthcare Life Sciences Conference is a premier event that brings together leading companies and investors in the healthcare and life sciences sectors. The conference features presentations from industry executives, providing insights into current trends, innovations, and investment opportunities.
About Annovis
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts. Stay informed about the latest developments by following us on LinkedIn, YouTube, and X.
Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, the Company's plans related to clinical trials. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include, but are not limited to, those related to patient enrollment, the effectiveness of buntanetap, and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety, and tolerability of buntanetap. Additional risk factors are detailed in the Company's periodic filings with the SEC, including those listed in the "Risk Factors" section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements in this press release are based on information available to the Company as of the date of this release. The Company expressly disclaims any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact:
Scott McGowan
InvestorBrandNetwork (IBN)
Phone: 310.299.1717
www.annovisbio.com/investors-relations
IR@annovisbio.com
FAQ
When is Annovis Bio (ANVS) presenting at the Oppenheimer Healthcare Conference 2025?
What will be discussed in Annovis Bio's (ANVS) Oppenheimer Conference presentation?
What is the current stage of Annovis Bio's (ANVS) Alzheimer's disease treatment?
What is buntanetap being developed for by Annovis Bio (ANVS)?
